Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first ...
On April 10, 2025 “Konkar Asteri” successfully completed her second special survey, with 12 days of work performed during the first quarter of 2025 and the remaining 10 days of work completed in April ...
As of September 23, 2025, Pyxis had 100% of available days for its MR product tankers fixed at an average estimated time charter equivalent (TCE) rate of $21,380 per day, along with 82% of available ...
The following slide deck was published by Pyxis Oncology, Inc. in conjunction with this event.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results